Comparative Pharmacology
Head-to-head clinical analysis: SULFONAMIDES DUPLEX versus TRIPLE SULFOID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFONAMIDES DUPLEX versus TRIPLE SULFOID.
SULFONAMIDES DUPLEX vs TRIPLE SULFOID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfonamides are competitive antagonists of para-aminobenzoic acid (PABA) and inhibit dihydropteroate synthase, blocking folate synthesis in susceptible bacteria.
Triple sulfoid (sulfadiazine, sulfamethazine, sulfamerazine) competes with para-aminobenzoic acid (PABA) to inhibit dihydropteroate synthase, blocking bacterial folate synthesis.
Oral: 500-1000 mg twice daily; maximum 2000 mg/day.
2 tablets orally every 6 hours for 10-14 days; each tablet contains sulfadiazine 270 mg, sulfamerazine 270 mg, and sulfamethazine 270 mg.
None Documented
None Documented
Terminal half-life: 7-12 hours in patients with normal renal function; prolonged to 24-50 hours in renal impairment (CrCl <30 mL/min) due to reduced elimination.
10-12 hours in normal renal function; prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min)
Renal: 70-100% unchanged drug via glomerular filtration and tubular secretion; fecal/biliary: <5%.
Renal: ~70% as unchanged drug; hepatic metabolism: ~20%; fecal: ~10%
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic